Tadalafil alleviates BPH symptoms by targeting the smooth muscle in the prostate and bladder neck. It does this primarily by inhibiting phosphodiesterase type 5 (PDE5).
- PDE5 normally breaks down cyclic guanosine monophosphate (cGMP), a molecule crucial for smooth muscle relaxation. By inhibiting PDE5, Tadalafil increases cGMP levels. Elevated cGMP promotes relaxation of smooth muscle in the prostate and bladder neck. This relaxation leads to improved urinary flow and reduced urinary symptoms.
The improved flow results from the decreased resistance to urine passage. This mechanism is distinct from its action in erectile dysfunction, although both involve PDE5 inhibition. While the primary effect is on the urinary tract, some studies suggest additional benefits, such as reduced inflammation.
Studies show a significant reduction in prostate volume in some patients treated with Tadalafil. Researchers believe this volume reduction may contribute to long-term improvement of BPH symptoms. However, further research is needed to fully understand this aspect of Tadalafil’s action in BPH.
Individual responses vary. It is vital to consult your physician for a personalized evaluation and treatment plan.
